AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.
Takeover action in biotech and speculative interest in small caps kept things interesting during an otherwise sleepy Monday, as everyone awaits Wednesday's Fed decision.
Appetite is growing for UNFI as the company is cutting debt and surpassing consensus earnings' estimates.
A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.